Both projects and programs are opportunities for direct member involvement to help benefit the biopharmaceutical manufacturing community, but they have some key complementary differences.
As of June 30, 2024
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Objectives
Requirements
Project Call 9.1 is now closed.
NIIMBL is pleased to announce Project Call 9.1, with member- driven and industry-led priority topic areas for technical development proposals.
Technology Topics:
Workforce Development Topics
RFA: Faculty Fellows
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
Objectives
Requirements
RFP: Project Call 9.1
Project Call 9.1 is now closed.
NIIMBL is pleased to announce Project Call 9.1, with member- driven and industry-led priority topic areas for technical development proposals.
Technology Topics:
Workforce Development Topics
NIIMBL funded 32 coronavirus response projects to multiple organizations across the United States.
NIIMBL awarded 11 new member-led technology, workforce development, and Global Health Fund projects with a value of ~$11.2 million.
December 2023
LigaTrap Technologies, LLC, Merck & Co., Inc., MilliporeSigma/EMD Serono, North Carolina State University, Rensselaer Polytechnic Institute
August 2023
North Carolina State University
August 2023
PATH Center for Vaccines Innovation & Access
August 2023
Fraunhofer USA
November 2022
Merck & Co., Inc., Pfizer, Inc., University of Maryland Baltimore
Mission
Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Vision
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
Mission
The Process Intensification Program accelerates innovative, flexible, and sustainable biopharmaceutical manufacturing by advancing intensified technologies through strong industry–academic collaboration.
Vision
To create a seamlessly integrated, highly intensified, and digitally connected manufacturing ecosystem that enables faster, more reliable, and sustainable delivery of lifechanging therapies.
Mission
Enable rapid, consistent, and scalable manufacturing of emerging preventive medical countermeasure platforms by advancing analytical understanding, improving process robustness, and creating data and tools that support industry adoption.
Vision
A biopharmaceutical ecosystem equipped with platform ready analytics, harmonized practices, and adaptable manufacturing approaches that accelerate time to clinic and time to market for high quality preventive medical countermeasures.
Learn more about the Preventive Medical Countermeasure Program
Mission
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
Vision
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
Big data
Mission
Accelerate the development and adoption of data-driven innovation and standards to increase the speed and resilience of biopharmaceutical manufacturing.
Vision
Data-driven technologies optimize the productivity of biopharmaceutical manufacturing and accelerate the delivery of high-quality medicines to patients.
Process intensification
Mission
The Process Intensification Program accelerates innovative, flexible, and sustainable biopharmaceutical manufacturing by advancing intensified technologies through strong industry–academic collaboration.
Vision
To create a seamlessly integrated, highly intensified, and digitally connected manufacturing ecosystem that enables faster, more reliable, and sustainable delivery of lifechanging therapies.
Preventive Medical Countermeasures
Mission
Enable rapid, consistent, and scalable manufacturing of emerging preventive medical countermeasure platforms by advancing analytical understanding, improving process robustness, and creating data and tools that support industry adoption.
Vision
A biopharmaceutical ecosystem equipped with platform ready analytics, harmonized practices, and adaptable manufacturing approaches that accelerate time to clinic and time to market for high quality preventive medical countermeasures.
Learn more about the Preventive Medical Countermeasure Program
Viral vector manufacturing & analytics
Mission
Develop and make broadly available a robust, economically viable, shared-access platform for the technical development, manufacturing, and characterization of AAV-based gene therapy vectors. Ensure that workforce training for this platform can integrate into existing curriculum or training models to encourage adoption, and integrate improvements into the platform based on feedback from these training programs.
Vision
A gene-based therapeutics industry capable of serving patients across the full spectrum of unmet needs—from prevalent indications to ultra-rare diseases—that has access to high-quality viral vectors without cost or speed limitations.
The NIIMBL eXperience is a hands-on, expenses-paid week-long program for college first years and sophomores to gain real-world insight into career possibilities in biopharmaceutical manufacturing.
It’s also an opportunity for NIIMBL academic or non-profit Member organizations to serve as regional lead organizations that will plan, recruit students, and run a NIIMBL eXperience program in their region.
The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member or at NIIMBL’s Headquarters in Delaware to support NIIMBL-led projects.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.